期刊
VIRUSES-BASEL
卷 15, 期 8, 页码 -出版社
MDPI
DOI: 10.3390/v15081674
关键词
rabies; lyssavirus; virus attenuation; PEP; antibody; scFv; rabies treatment
类别
The rabies virus is responsible for over 59,000 human deaths per year and is difficult to treat in endemic areas. To overcome this, researchers developed a live-attenuated recombinant rabies virus expressing a highly neutralizing antibody linked to a fluorescent marker. This approach shows promise for the development of a therapeutic live-attenuated virus-based treatment for rabies infection.
Rabies virus (RABV) causes possibly the oldest disease and is responsible for an estimated >59,000 human fatalities/year. Post exposure prophylaxis (PEP), the administration of vaccine and rabies immunoglobulin, is a highly effective tool which is frequently unavailable in RABV endemic areas. Furthermore, due to the constraints of the blood-brain barrier, current PEP regimes are ineffective after the onset of clinical symptoms which invariably result in death. To circumvent this barrier, a live-attenuated recombinant RABV expressing a highly RABV-neutralising scFv antibody (62-71-3) linked to the fluorescent marker mCherry was designed. Once rescued, the resulting construct (named RABV-62scFv) was grown to high titres, its growth and cellular dissemination kinetics characterised, and the functionality of the recombinant 62-71-3 scFv assessed. Encouraging scFv production and subsequent virus neutralisation results demonstrate the potential for development of a therapeutic live-attenuated virus-based post-infection treatment (PIT) for RABV infection.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据